Estrogen and Microvascular Function

NCT06043310 — Active not recruiting, 45 participants, Medical College of Wisconsin

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Effects of Continuous Estrogen on Human in Vivo Microvascular Function

RegistryNCT06043310
StatusActive not recruiting
Study typeObservational
Enrollment45 (Estimated)
SponsorMedical College of Wisconsin (Other)
ConditionsEstrogen, Cardiovascular Diseases, Microvasculature, Oral Contraceptive Use
InterventionsNω-nitro-L-arginine methyl ester (L-NAME), Acetylcholine, Sodium Nitroprusside (Drug)
Datesstart 2023-10-12, primary completion 2031-12-01 (estimated), completion 2031-12-01 (estimated), first posted 2023-09-21, last updated 2026-07-29
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
All trials for Estrogen All trials for Cardiovascular Diseases All trials of Nω-nitro-L-arginine methyl ester (L-NAME) All trials of Acetylcholine

-Summary

The goal of this study is to learn how long-term use of estrogen affects blood vessels in healthy adults.

Participants will:

* give one blood draw of 5 mL
* have one Dexa Scan taken to measure adipose and muscle mass
* have a camera placed under the tongue to take pictures of blood vessels
* have 2 laser Doppler microdialysis catheters placed on the forearm to monitor blood vessels before and after local drug infusion

Researchers will compare blood vessel function of those who take estrogen to those who do not.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
Continuous estrogen/progestinDrug: Nω-nitro-L-arginine methyl ester (L-NAME); Drug: Acetylcholine; Drug: Sodium NitroprussideFemales who have had continuous estrogen/progestin treatment for a minimum of 1 year.
No Estrogen/progestinDrug: Nω-nitro-L-arginine methyl ester (L-NAME); Drug: Acetylcholine; Drug: Sodium NitroprussideFemales who have not had continuous estrogen treatment for a minimum of 5 years.
Continuous progestinDrug: Nω-nitro-L-arginine methyl ester (L-NAME); Drug: Acetylcholine; Drug: Sodium NitroprussideFemales who have had continuous progestin treatment for a minimum of 1 year.
  • Nω-nitro-L-arginine methyl ester (L-NAME) (Drug): L-NAME will be infused locally through microdialysis catheters.
  • Acetylcholine (Drug): ACh will be infused locally through microdialysis catheters.
  • Sodium Nitroprusside (Drug): SNP will be infused locally through microdialysis catheters.

+Outcome measures

Primary outcomes

  • Change in blood vessel dilation [2 hours]: Cutaneous vascular conductance in response to acetylcholine, L-NAME, and sodium nitroprusside infusions will be calculated as percentage of cardiovascular conductance.
  • Change in Perfused Vessel Density [0.5 hours]: Total vessel density (TVD) will be calculated using the DeBacker Score manual analysis on all images that have a minimum microcirculation image quality score (MIQS) of 10. Perfused vessel density (PVD) will be calculated by multiplying total vessel density (TVD) x proportion of perfused vessels (PPV%).

+Eligibility

Sex: Female, ages: 18 Years to 40 Years, accepts healthy volunteers

Inclusion Criteria:

Estrogen/Progestin Group

* Adults aged 18-40 years
* Females with estrogen/progestin treatment for a minimum of 1 year.
* Blood pressure <140/ < 90 mmHg
* No more than 1 cardiovascular risk factor Control Groups
* Adults aged 18-40 years
* Female with no estrogen/progestin treatment for minimum of 5 years.
* Female undergoing progestin only treatment for a minimum of 1 year.
* Blood pressure <140/ < 90 mmHg
* No more than 1 cardiovascular risk factor

Exclusion Criteria:

* Medications that could alter cardiovascular control
* Rash, skin disease, or pigmentation disorders on both forearms
* Anemia
* Kidney Disease
* Known skin allergies
* Smoking or tobacco use within last 6 months
* Coronary Artery Disease

  -1 cardiovascular risk factor Hypertension Diabetes Hypercholesterolemia Hyperlipidemia
* Bleeding disorders
* Use of anti-coagulants
* Allergies to study drugs
* Use of topical/non-topical steroids in last 6 months
* Internal mouth sores
* Forearms covered with tattoos
* Pregnancy

+Locations (1)

FacilityCityCountryStatus
Froedtert HospitalWauwatosa, WisconsinUnited States